作者
Mostafa Eltobgy,Ashley Zani,Adam D. Kenney,Shady Estfanous,Eunsoo Kim,Asmaa Badr,Cierra Carafice,Kylene P. Daily,Owen Whitham,Maciej Pietrzak,Amy Webb,Jeffrey Kawahara,Adrian C. Eddy,Parker Denz,Mijia Lu,Mahesh KC,Mark E. Peeples,Jiànróng Lǐ,Jian Zhu,Jianwen Que,Richard Robinson,Oscar Rosas Mejia,Rachael E. Rayner,Luanne Hall‐Stoodley,Stéphanie Seveau,Mikhail A. Gavrilin,Xiaoli Zhang,J. Thomas,Jacob E. Kohlmeier,Mehul S. Suthar,Eugene M. Oltz,Andrea Tedeschi,Frank Robledo‐Avila,Santiago Partida‐Sánchez,Emily A. Hemann,Eman Abdelrazik,Adriana Forero,Shahid M. Nimjee,Prosper N. Boyaka,Estelle Cormet‐Boyaka,Jacob S. Yount,Amal O. Amer
摘要
Significance We report the discovery of fundamental roles for the noncanonical inflammasome molecule Caspase-4/11 in promoting pathological inflammatory and prothrombotic pathways in severe acute respiratory syndrome coronavirus 2 (SARS–CoV-2) infections. Our work demonstrates that Caspase-11 has a broader role in immune responses beyond its previously appreciated effects in bacterial infections. Further, we show that Caspase-11–deficient mice infected with SARS–CoV-2 fare significantly better in terms of overall illness, lung inflammation, and thrombosis than wild-type (WT) mice, thus implicating Caspase-11 as a new therapeutic target for preventing or treating COVID-19.